孟鲁斯特钠联合匹多莫德治疗儿童哮喘临床疗效观察

目的探讨孟鲁斯特钠联合匹多莫德治疗儿童哮喘的应用价值。方法将117例非急性发作期哮喘患儿,随机分为观察Ⅰ组、Ⅱ组和对照组。观察Ⅰ组给予孟鲁斯特钠4 mg,1次/晚,口服,匹多莫德400 mg,1次/晚,口服;Ⅱ组给予孟鲁斯特钠4 mg,1次/晚,口服;对照组经常规止咳、平喘及必要时抗感染治疗。三组均观察12周。结果无哮喘症状的天数、医生评价明显好转率、有1次以上哮喘发作的例数以及需全身用糖皮质激素治疗的例数,观察Ⅰ组与Ⅱ组优于对照组（P〈0.01）,观察Ⅰ组优于观察Ⅱ组（P〈0.01或0.05）。每周日、夜间哮喘症状计分：观察Ⅰ、Ⅱ组优于对照组,观察Ⅰ组优于观察Ⅱ组（P〈0.01或0.05）。结论孟鲁斯特钠联合匹多莫德治疗儿童哮喘疗效显著,高于孟鲁斯特钠单独应用和常规治疗方法。

Observation on clinical efficacy of Montelukast sodium combined with Pidotimod for children with asthma

Objective To discuss the application value of Montelukast sodium combined with Pidotimod for children with asthma. Methods 117 cases of patients with non-acute attack of asthma randomly divided into observation group Ⅰ,Ⅱ and control group.For observation Ⅰ group,oral intake Montelukast sodium 4mg and Pidotimod 400mg one time per night;for groupⅡ,oral intake Montelukast sodium 4mg one time per night;the control group was treated with relieving cough and asthma and anti-infection treatment.3 groups were observed for 12 weeks. Results The number of days without asthma symptoms,the obvious recovery rate of doctor＇s evaluation,the cases of asthma attack more than once and the cases of asthma of systemic corticosteroid therapy,observation groupⅠ,Ⅱ are superior to control group（P0.01）.Observation groupⅠ is superior to observation group Ⅱ（P0.01 or 0.05）.Asthma symptoms score of day and night weekly： observation groupⅠ,Ⅱ are superior to control group,observation groupⅠ is superior to observation group Ⅱ（P0.01 or 0.05）. Conclusion The therapy of Montelukast sodium combined with Pidotimod has significant curative effect for children with asthma,exceeding Montelukast sodium used alone and conventional treatments.